Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323621 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
- 20
- Study locations
NCT01323621 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 512 participants, below the 1,037-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01323621, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.
Conditions Studied
Interventions
- DRUG Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
- DRUG Fluticasone Propionate 250mcg / salmeterol 50mcg
- DRUG Double-dummy placebo
- DRUG Salbutamol as needed
Study Locations (20)
South Carolina
- GSK Investigational Site - Gaffney
- GSK Investigational Site - Orangeburg
- GSK Investigational Site - Seneca
- GSK Investigational Site - Spartanburg
Campania
- GSK Investigational Site - Naples
- GSK Investigational Site - San Felice A Cancello Caserta
- GSK Investigational Site - Telese Terme (BN)
Alabama
- GSK Investigational Site - Jasper
California
- GSK Investigational Site - Riverside
Florida
- GSK Investigational Site - DeLand
Idaho
- GSK Investigational Site - Coeur d'Alene
Minnesota
- GSK Investigational Site - Minneapolis
Ohio
- GSK Investigational Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2011-03-18 |
| Est. Completion | 2012-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323621
The ClinicalTrials.gov registry entry for NCT01323621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,037-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (51% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 4 interventions - of which Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg is the first listed.
NCT01323621 reports 20 study locations spanning 15 distinct geographic areas - top geographies include South Carolina, Campania, Alabama.
Frequently Asked Questions
What is clinical trial NCT01323621 about?
NCT01323621 is a clinical study titled "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.
What is the current status of trial NCT01323621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2011-03-18. Estimated completion is 2012-01-24.
What conditions does trial NCT01323621 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT01323621?
The interventions under investigation include: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg (DRUG), Fluticasone Propionate 250mcg / salmeterol 50mcg (DRUG), Double-dummy placebo (DRUG), Salbutamol as needed (DRUG).
Who is sponsoring clinical trial NCT01323621?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01323621 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Idaho, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.